Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.

ABSTRACT:

SUBMITTER: Tree AC 

PROVIDER: S-EPMC7617972 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature